NCT00322556View on ClinicalTrials.gov

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

PHASE3CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
AgammaglobulinemiaIgG DeficiencyCommon Variable Immunodeficiency
Interventions
DRUG

Immunoglobulins Intravenous (Human)

Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw

Trial Locations (10)

33408

Contact CSL Behring for facility details, North Palm Beach

33701

Contact CSL Behring for facility details, St. Petersburg

46202

Contact CSL Behring for facility details, Indianapolis

46815

Contact CSL Behring for facility details, Fort Wayne

52242

Contact CSL Behring for facility details, Iowa City

55905

Contact CSL Behring for facility details, Rochester

75230

Contact CSL Behring for facility details, Dallas

80112

Contact CSL Behring for facility details, Centennial

90027

Contact CSL Behring for facility details, Los Angeles

63104-1095

Contact CSL Behring for facility details, St Louis

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY

NCT00322556 - Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) | Biotech Hunter | Biotech Hunter